Yingji Jin

By Jeonghwan Bae, Hyerim Park, Yingji Jin, and Janet Lee, Samsung Biologics Determining developability and accelerating feasibility studies can greatly improve a drug's chances of moving through development. By using an optimized transient transfection platform, drug developers can accelerate their characterization and early development activities, facilitating continuity for a drug's scale-up.

Connect with researchers from around the world for a deep dive into solutions for optimizing bioprocessing, and immerse yourself at the forefront of innovation at CHI's Bioprocessing Summit. Leaders from top pharma, biotech, academic, and governmental institutions will convene on August 19-22 in Boston and online for cutting-edge presentations, live breakout groups, poster sessions, collaboration, networking, and more. Learn more at BioprocessingSummit.com.

Get more pharma outsourcing insight with our FREE newsletter Article | February 2, 2024 By Sewon Park, Yingji Jin, and Janet Lee, Cell Line Development Group, Samsung Biologics From a manufacturing perspective, controlling the degree of sialylation for a product is crucial, as it has an outsized impact on the quality and stability of therapeutic glycoproteins.